It can make it difficult to eat certain foods, difficult to get adequate nutrients, and generally just difficult to function ...

Thus, our team has begun developing and conducting treatment studies to test rehabilitative paradigms that are based on this fundamental neuroscience knowledge. The Intensive Dysphagia Rehabilitation ...

Current treatment include using food thickeners, liquidising meals and referral to speech and language therapist (SLT) for swallowing therapy. In the past, scientists thought that dysphagia was caused ...

Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject ...

Although mostly asymptomatic, the retroesophageal and retrotracheal course of the lusorian artery might result in unspecific thoracic pain, dysphagia ... endovascular treatment, and a combined ...

Dysphagia can be categorized as oropharyngeal ... and coexisting conditions guide the overall approach to treatment. Efficacy is based on clinical response instead of antibody titers.

Conditions like thrush, strep throat (bacterial tonsils), or other infections affecting the throat can cause pain and inflammation that lead to temporary dysphagia. Treatment for head and neck cancers ...

If you notice any signs or symptoms of dysphagia, it is imperative to consult a deglutologist for a comprehensive evaluation and appropriate treatment. Deglutologists are specialized allied health ...

Top quality health care requires a team of skilled professionals working in collaboration with doctors and nurses ...

Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis: Victoria, British Columbia Thursday, November 14, 2024, ...

Clinical research goals are the development of novel and robust evaluation and treatment techniques for dystussia and dysphagia. Our current projects focus on multiple behaviors contributing to airway ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...